Managing Conflicts of Interest at the IRB and Institutional Level: INSTITUTIONAL CONFLICTS OF INTEREST Claudia R. Adkison, J.D., Ph.D. Executive Associate.

Slides:



Advertisements
Similar presentations
VCOM Conflict of Interest Policy Overview of Financial Conflict of Interest Related to Research December 4, 2013.
Advertisements

Financial Conflict of Interest July 2012 rev
Disclosure Reporting for Conflicts of Interest and Commitment Conflict of Interest Program UTMB Research Services.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Conflict of Interest (COI) Objectives: Provide an overview of financial conflict of interest (FCOI) related to research activities at Gillette Describe.
Responsible Conduct in Research Conflict of Interest and Commitment.
1 UMass Dartmouth Conflicts of Interest Policies UMass Dartmouth Liz Rodriguez February 17, 2011.
IRB Member Conflict of Interest Presentation for IRB Members.
Conflict of Interest Presented by Barbara L. Shiels Associate General Counsel February 2009.
Conflict of Interest/Conflict of Commitment NCURA Region VI & VII Spring Meeting Chandler, AZ April 2005.
Conflict of Interest: Dartmouth College. Why do we care about it ? Conflict of Interest in Research : Unbiased research: design, conduct, reporting Maintain.
Personal financial benefit or economic interest from one’s position that may inappropriately: influence the employee’s judgment compromise the employee’s.
Financial Conflict of Interest (FCOI) Updates Office of Sponsored Programs April 2014.
NIH FINANCIAL CONFLICT OF INTEREST REGULATIONS – 2012 Office of Sponsored Programs Research & Graduate Studies.
Presented by: David E. Broome, Jr. Vice Chancellor and General Counsel Carl P.B. Mahler, II Executive Director, Office of Technology Transfer October 30,
RESEARCH CONFLICTS OF INTEREST Steven J. Norris, PhD Greer Professor and Vice Chair for Research Department of Pathology and Laboratory Medicine Chair,
For VA Facilities-Identifying and Managing Institutional Conflict of Interest Peter A. St. Arnold Administrative Officer and Director of Operations For.
Conflicts of Interest in Research: Policies and Regulations Marie Barron, M.A., COI Program Specialist Rick Lyons, M.D., Ph.D., COI Committee C Chair.
Conflict of Interest and Technology Transfer Sherrie Settle Assistant Director, Research Compliance Program Institutional Conflict of Interest Officer.
Conflict of Interest Faculty & Staff of Instruction or Research Human Resources 2011.
Chapter 11.  The board is ultimately responsible for risk management  Oversee strategic risks, operational risks, and financial risks  Many federal.
Financial Conflict of Interest
COI Management Planning A guide and tutorial to assist with the development and drafting of a Conflict of Interest Management Plan.
Internal Auditing and Outsourcing
ECOI electronic Conflict of Interest User Guide 1 Emory University, Office of Research Administration.
Rice’s New Staff Conflict of Interest Policy and Procedures Administrators’ Forum Richard A. Zansitis General Counsel April 2008.
Conflict of Interest Michelle Stickler, DEd Office for Research Protections
Copyright © 2008 McGraw-Hill Ryerson Ltd.1 Chapter Twelve Corporate Governance Canadian Business and Society: Ethics & Responsibilities.
By: 1. Kenneth A. Kim John R. Nofsinger And 2. A. C. Fernando.
Research Conflicts of Interest: Identifying and Minimizing COI from the Perspectives of Sponsors, Faculty and the IRB Research Conflicts of Interest: Identifying.
UNM and Health System Internal Audit Departments Internal Audit Department Orientation Manu Patel, Internal Audit Director Purvi Mody, Executive Director,
Conflicts of Interest Brenda Seiton, J.D. Assistant Dean for Administration Department Administrators Course September 1, 2006.
MANAGING CONFLICTS OF INTEREST IN UM/JHS HUMAN SUBJECT RESEARCH 1.GENERAL PRINCIPALS AND PROCEDURES 2. REGULATIONS, POLICIES AND UM PROCESS Human Subjects.
 Tracy L. LeGrow, Psy.D. Associate Professor Department of Psychiatry and Behavioral Medicine.
CONFLICTS OF INTEREST PRESENTED BY THE UMMC OFFICE OF INTEGRITY AND COMPLIANCE.
Best Practices: Financial Resource Management February 2011.
Sarbanes Oxley Act. The Sarbanes Oxley Act consists of 11 Sections I – Public Company Accounting Oversight Board II – Auditor independence III – Corporate.
CONFLICTS OF INTEREST ARE HERE TO STAY: PROTECTING SCIENCE FROM BIAS Susan S. Ellenberg, Ph.D. Center for Biologics Evaluation and Research, FDA Boston,
Managing Your Grant Award August 23, 2012 Janet Stoeckert Director, Research Administration Sr. Administrator, Basic Sciences Keck School of Medicine 1.
1 Conflict of Interest: A Tricky Issue for Universities Karen Hersey, Professor Franklin Pierce University Nonprofit Technology Transfer Course November.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
Fight On Training on NIH Conflict of Interest Rule and Introduction to diSClose Dan Shapiro Director, Research Compliance Ben Bell Manager, Research Compliance.
Faculty Council on Research April 11, 2012 Jeff Cheek, Ph.D. UW Associate Vice Provost for Research Compliance and Operations New PHS regulations on financial.
Conflict of Interest in Human Subjects Research Bette-Jane Crigger, PhD.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
CONFLICTS OF INTEREST: RECOGNITION AND MANAGEMENT Judith L. Curry Associate General Counsel NC State University March 5, 2007.
ECON 308 Week 15 Corporate Governance Chapter 18 1.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
Conflicts of Interest in the Academy: Recognition and Management Dave Broome Senior Associate General Counsel NC State University 20 March 2002.
Board Leadership Seminar: The Corporation & Its Board September 15, 2015.
Stanford Policy – Faculty ◦ Mission: Promote public good by transferring knowledge  Consulting  Technologies arising from research These activities can.
Conflicts of Interest in Research : Perspective of the IRB Human Subject Protections Monika S. Markowitz, PhD Director, Office of Research Compliance and.
Company: Cincinnati Insurance Company Position: IT Governance Risk & Compliance Service Manager Location: Fairfield, OH About the Company : The Cincinnati.
Second Annual Medical Research Summit March 25, 2002 Washington, D.C.
Fifteenth Board Meeting Geneva, April 2007 Ethics Committee Annual Report Professor Sheila Dinoshe Tlou, M.P., POH (Chair) Dr Brian Brink (Vice Chair)
Lecture 5 Control and AIS Copyright © 2012 Pearson Education 7-1.
Michael Scian, MBA, JD Assistant Director of Compliance University of Florida.
eCOI electronic Conflict of Interest
Kyle Conner, MA, CIP Associate Director, Office of Human Research
IRB Open House Conflicts of Interest and Financial Conflicts of Interest in Research May 19, 2017 Office of Policy Coordination, Division of Outside.
Kyle Conner, MA, CIP Associate Director, Office of Human Research
UW Conflict of Interest Program Manager Office of Research Policy
Research Integrity Office (RIO)
Board of Directors Roles and Responsibilities
Promotion on the Clinician Educator and Clinical Practice Tracks
Disclosure of conflicts of interest – explanation
Financial Conflict of Interest in Research SEMINAR
Disclosure of conflicts of interest
Disclosure of conflicts of interest
Financial Conflict of Interest in Research SEMINAR
Presentation transcript:

Managing Conflicts of Interest at the IRB and Institutional Level: INSTITUTIONAL CONFLICTS OF INTEREST Claudia R. Adkison, J.D., Ph.D. Executive Associate Dean Administration and Faculty Affairs Emory University School of Medicine PRIM&R Meeting, Boston, MA May 3-5, 2004

TO MAINTAIN THE PUBLIC TRUST... Institutional officials must Make decisions and policies for the institution that are free from improper bias or conflict of interest Be able to document that they have done so

COMPETING INTERESTS The institution has interests in Its financial gain from external entities – donors, research sponsors, companies, Board and Officer investments Its own academic and clinical missions and the policies that support them – allocations of space, money, people; review and approval processes; monitoring, auditing, compliance, and discipline Its reputation Its research integrity The safety and welfare of its human subjects

INSTITUTIONAL CONFLICT OF INTEREST (ICOI) When the financial interests of the institution, or of an institutional official acting in his/her official capacity, or of IRB members, might affect or appear to affect Any phase of its research mission -- conduct, review, oversight and compliance, outcome Finances and economic status of the institution Missions of the institution Appropriate vendor relationships Employment practices

POTENTIAL ICOI (RESEARCH) When the institution (or institutional officials who manage or oversee research or IRB members): Might get royalties from the sale of the product that is to be investigated Holds any equity through licensing its technology to a non-publicly traded research sponsor (e.g., startup company) Holds ownership interests >$100K through licensing its technology to a publicly-traded research sponsor Gets a significant gift from a potential research sponsor

POTENTIAL ICOI (RESEARCH) (2) When an institutional official who has research responsibility has a Significant financial interest in the research sponsor or the product to be investigated –Equity interest –Consulting relationship –Honoraria, gifts –Service as officer, board member Purchasing relationship with the research sponsor (vendor)

RULES AND REGULATIONS ON ICOI Various regulations and statutes govern ICOI in finance, employment, Board duties, etc. (IRS, SEC, corporate law... ) No federal regulations on ICOI in research Excellent guidance for institutions engaged in human subject research, adaptable to broader application: –Protecting Subjects, Preserving Trust, Promoting Progress II: Principles & Recommendations for Oversight of an Institution’s Financial Interests in Human Subjects Research AAMC Task Force on Financial Conflicts of Interest in Clinical Research, October 2002

HYPOTHETICAL CASE 1: Department Chair Chair of the Department of Pathology has a startup company that proposes to sponsor the research of Dr. Doe, Asst Professor of Pathology Chair’s authority raises this to an ICOI –Issues with internal as well as external perceptions Some options (consider basic science v. clinical research) –Prohibit the sponsorship –Transfer oversight of Dr. Doe to another Dept Chair for evaluation, salary, promotion, space, resources considerations, research oversight

HYPOTHETICAL CASE 2: Department Chair Department Chair has an extensive consulting relationship with a company that proposes to sponsor the Chair’s research – personal COI. Chair assigns the project to Asst Prof Doe as PI but will remain involved Arguably an ICOI, since the authority of Chair could influence the outcome –Plan: Remove the Chair from the project; require an unbiased expert to review the manuscript and data –Argument: Young professors benefit from the Chair’s advice and mentoring Basic v. clinical considerations in management

HYPOTHETICAL CASE 3: EVP, DEAN, COO EVP/Dean/COO invests $50K to take institutional equity in Dr. Path’s startup company to develop vaccines (in good but short-sighted faith!) Suggestion: Limit financial oversight and investment to Board, institutional CFO (per AAMC advice) –But medical EVPs and Deans may not want to turn over their discretionary accounts to Board and CFO for management and investment –Blanket rules do not fit every institution

HYPOTHETICAL CASE 3: EVP, DEAN, COO (2) Suggested options –Establish an external holding company to manage institutional equity holdings –Have an institutional committee outside the control of the EVP/Dean/COO make or review all further decisions related to the investment –Prohibit such investments entirely Investment was a short-sighted decision because...

HYPOTHETICAL CASE 4: Tech Transfer Officer and Boss Dr. Path asks institution to license the vaccine technology that he generated to his company –ICOI because institution has equity in company, would receive royalties –ICOI because Dr. Path is a conflicted institutional officer Institution has duty to ensure that the technology is transferred in the way that is most likely to benefit the public Plan: Have the technology independently evaluated for value and for other markets By whom? Who pays?

HYPOTHETICAL CASE 5: EVP, DEAN, COO Institution licenses its vaccine technology to Prof. Doe’s company, in which the institution holds equity. Institution will receive royalties from the sale of the vaccine Company proposes to sponsor clinical research at institution to test the vaccine Options –Set up a management plan for disclosures, research and data oversight, and oversight of patient involvement that puts EVP, DEAN, COO at arm’s length AND –Have an external review board monitor the management plan

HYPOTHETICAL CASE 6: SERVICE CHIEF Dr. Smith routinely recommends the surgical sutures, stents, and other devices purchased by the hospital. Dr. Smith is compensated >$10K as a consultant for the suture company, as a speaker for the stent company, and holds >$20K stock in the device company. –ICOI with the institutional vendor policy –Prior disclosure by all who influence purchasing

A FEW SIMPLE RULES A FEW SIMPLE RULES Separate the roles of administrators who oversee and make institutional decisions about research from those who oversee investments and technology transfer Have established policies and procedures for the identification, disclosure, review, and management or elimination of potential ICOI Have an ICOI Committee with some external members, high-ranking independent internal members (not COI Committee) Make use of external committees, ad hoc or standing, routinely or in certain cases, if feasible

A FEW SIMPLE RULES (2) A FEW SIMPLE RULES (2) Have good communication among the ICOI Committee, COI Committee(s), Tech Transfer Office, and IRB Disclose, disclose, disclose Require IRB members to disclose potential conflicts of interest and recuse or divest if appropriate